Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Equities researchers at Cantor Fitzgerald decreased their FY2017 earnings estimates for Aldeyra Therapeutics in a report released on Sunday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will earn ($1.34) per share for the year, down from their prior forecast of ($1.30). Cantor Fitzgerald currently has a “Overweight” rating and a $22.00 target price on the stock.

Several other equities analysts have also commented on ALDX. HC Wainwright set a $18.00 price target on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Thursday, August 10th. ValuEngine lowered shares of Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Canaccord Genuity reiterated a “buy” rating and issued a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $14.00 price target (up from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Aldeyra Therapeutics has an average rating of “Buy” and an average target price of $17.29.

COPYRIGHT VIOLATION NOTICE: “FY2017 Earnings Estimate for Aldeyra Therapeutics, Inc. (ALDX) Issued By Cantor Fitzgerald” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/fy2017-earnings-estimate-for-aldeyra-therapeutics-inc-aldx-issued-by-cantor-fitzgerald/1704246.html.

Aldeyra Therapeutics (NASDAQ:ALDX) opened at $6.05 on Wednesday. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $11.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09.

Several institutional investors and hedge funds have recently made changes to their positions in ALDX. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $132,000. Hikari Power Ltd grew its position in shares of Aldeyra Therapeutics by 186.4% during the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after acquiring an additional 70,196 shares during the last quarter. Sphera Funds Management LTD. grew its position in shares of Aldeyra Therapeutics by 31.0% during the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock worth $4,117,000 after acquiring an additional 207,431 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after acquiring an additional 9,407 shares during the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in shares of Aldeyra Therapeutics during the second quarter worth approximately $104,000. Institutional investors and hedge funds own 40.34% of the company’s stock.

In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the stock in a transaction dated Tuesday, September 19th. The shares were acquired at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 28.40% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.